Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

CSPI CRITICIZES EFIDAC/24, SOURCE OF LIFE 1993 AD CAMPAIGNS

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

CSPI CRITICIZES EFIDAC/24, SOURCE OF LIFE 1993 AD CAMPAIGNS at a Jan. 27 press conference to announce the recipients of the consumer group's Ninth Annual "Harlan Page Hubbard Lemon Awards" for "misleading" advertising. According to the Center for Science in the Public Interest, Ciba's Efidac/24 ads are deceptive because they urge "cold sufferers to rely on 24-hour, time-release Efidac/24, even though the product contains pseudoephedrine hydrochloride, which can cause sleeplessness." Ads for Nature's Plus' Source of Life dietary supplement were cited by CSPI because they claim to deliver "'an incredible burst of energy' the very first time you try it."

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

See All
UsernamePublicRestriction

Register

PS082510

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By